Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean A Boutin

Showing results (1-10 of 176) with videos related to

Pageof 18
Sort By:
Current Opinion in Pharmacology|September 4, 2009
Progress and new fields in molecular pharmacologyJean A Boutin
Journal De La Societe De Biologie|September 1, 2007
[Melatonin binding site MT3 is QR2: state of the art]Jean A Boutin
Expert Opinion on Therapeutic Targets|October 15, 2015
Quinone reductase 2 as a promising target of melatonin therapeutic actionsJean A Boutin
Medecine Sciences : M/S|January 21, 2022
[Melatonin: A short clarification for the over-enthusiasts]Jean A Boutin
Journal of Pineal Research|October 27, 2020
Melatonin controversies, an updateJean A Boutin, Ralf Jockers
The Journal of Pharmacology and Experimental Therapeutics|November 4, 2018
Is There Sufficient Evidence that the Melatonin Binding Site <i>MT</i> Is Quinone Reductase 2?Jean A Boutin, Gilles Ferry
Pharmacology Research & Perspectives|January 2, 2020
The five dimensions of receptor pharmacology exemplified by melatonin receptors: An opinionJean A Boutin, Céline Legros
Methods in Molecular Biology (Clifton, N.J.)|September 30, 2022
Detection of Melatonin in Tissue SamplesCéline Legros, Jean A Boutin
Methods in Molecular Biology (Clifton, N.J.)|September 30, 2022
Measurement of NQO2 Catalytic Activity and of Its Inhibition by MelatoninGilles Ferry, Jean A Boutin
Cellular Signalling|April 17, 2002
Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?Olivier Nosjean, Jean A Boutin
Pageof 18

Showing results (1-10 of 176) with videos related to

Sort By:
Pageof 18
Current Opinion in Pharmacology|September 4, 2009
Progress and new fields in molecular pharmacologyJean A Boutin
Journal De La Societe De Biologie|September 1, 2007
[Melatonin binding site MT3 is QR2: state of the art]Jean A Boutin
Expert Opinion on Therapeutic Targets|October 15, 2015
Quinone reductase 2 as a promising target of melatonin therapeutic actionsJean A Boutin
Medecine Sciences : M/S|January 21, 2022
[Melatonin: A short clarification for the over-enthusiasts]Jean A Boutin
Journal of Pineal Research|October 27, 2020
Melatonin controversies, an updateJean A Boutin, Ralf Jockers
The Journal of Pharmacology and Experimental Therapeutics|November 4, 2018
Is There Sufficient Evidence that the Melatonin Binding Site <i>MT</i> Is Quinone Reductase 2?Jean A Boutin, Gilles Ferry
Pharmacology Research & Perspectives|January 2, 2020
The five dimensions of receptor pharmacology exemplified by melatonin receptors: An opinionJean A Boutin, Céline Legros
Methods in Molecular Biology (Clifton, N.J.)|September 30, 2022
Detection of Melatonin in Tissue SamplesCéline Legros, Jean A Boutin
Methods in Molecular Biology (Clifton, N.J.)|September 30, 2022
Measurement of NQO2 Catalytic Activity and of Its Inhibition by MelatoninGilles Ferry, Jean A Boutin
Cellular Signalling|April 17, 2002
Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part?Olivier Nosjean, Jean A Boutin
Pageof 18